2023
Low-dose interleukin-2 promotes immune regulation in face transplantation: A pilot study
Murakami N, Borges T, Win T, Abarzua P, Tasigiorgos S, Kollar B, Barrera V, Ho Sui S, Teague J, Bueno E, Clark R, Lian C, Murphy G, Pomahac B, Riella L. Low-dose interleukin-2 promotes immune regulation in face transplantation: A pilot study. American Journal Of Transplantation 2023, 23: 549-558. PMID: 36740193, PMCID: PMC10318113, DOI: 10.1016/j.ajt.2023.01.016.Peer-Reviewed Original ResearchConceptsLow-dose IL-2 therapyIL-2 therapySkin allograftsFace transplant recipientsTransplant recipientsIL-2Immune regulationLow-dose interleukin-2 (IL-2) therapyHigher acute rejection ratesLow-dose IL-2Face transplantationAcute rejection ratesCytotoxicity-associated genesDose interleukin-2Greater suppressive functionInterleukin-2 therapyAutoimmune hemolytic anemiaRegulatory T cellsNarrow therapeutic windowLife-changing procedureImmunological monitoringTim-3Peripheral bloodImmune modulationHemolytic anemia
2022
T cell-attracting CCL18 chemokine is a dominant rejection signal during limb transplantation
Borges T, Abarzua P, Gassen R, Kollar B, Lima-Filho M, Aoyama B, Gluhova D, Clark R, Islam S, Pomahac B, Murphy G, Lian C, Talbot S, Riella L. T cell-attracting CCL18 chemokine is a dominant rejection signal during limb transplantation. Cell Reports Medicine 2022, 3: 100559. PMID: 35492875, PMCID: PMC9040185, DOI: 10.1016/j.xcrm.2022.100559.Peer-Reviewed Original ResearchConceptsLimb transplantationTransplant recipientsSkin antigen-presenting cellsSolid organ transplant recipientsAccelerated graft rejectionOrgan transplant recipientsSkin transplantation modelAntigen-presenting cellsLife-changing procedureImmunosuppressive approachesTh17 cellsGraft rejectionGreater immunogenicityCell infiltrationSkin biopsiesTransplantation modelSkin xenograftsChemokine CCL18Immune moleculesTransplantationCCL18RecipientsMolecular characterizationChemokinesCCR8 receptor
2016
Codominant Role of Interferon‐γ– and Interleukin‐17–Producing T Cells During Rejection in Full Facial Transplant Recipients
Borges T, O'Malley J, Wo L, Murakami N, Smith B, Azzi J, Tripathi S, Lane J, Bueno E, Clark R, Tullius S, Chandraker A, Lian C, Murphy G, Strom T, Pomahac B, Najafian N, Riella L. Codominant Role of Interferon‐γ– and Interleukin‐17–Producing T Cells During Rejection in Full Facial Transplant Recipients. American Journal Of Transplantation 2016, 16: 2158-2171. PMID: 26749226, PMCID: PMC4979599, DOI: 10.1111/ajt.13705.Peer-Reviewed Original ResearchConceptsDe novo donor-specific antibody developmentDe novo donor-specific antibodiesInterleukin-17-producing T cellsT helper 2 cell phenotypeFacial transplantationDonor-specific antibody developmentNovo donor-specific antibodiesChemotactic protein-1 levelsPeripheral blood mononuclear cellsAcute cellular rejectionAnti-HLA antibodiesDonor-specific antibodiesFollicular helper cellsImmune cell subsetsProtein-1 levelsBlood mononuclear cellsMedium-term outcomesSkin biopsy specimensFull facial transplantationCellular rejection processLife-changing procedureCellular rejectionCodominant roleDonor alloreactivityTransplant recipients